Skip to main content
Jason Karlawish, MD, Geriatrics, Philadelphia, PA, Penn Presbyterian Medical Center

JasonHKarlawishMD

Geriatrics • Philadelphia, PA

Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania Perelman School of Medicine Director of the Penn Neurodegenerative Disease Ethics and Policy Program Associate Director of the Clinical Core and Co-Associate Director of the Alzheimer’s Disease Core Center Co-Director of the Penn Memory Center Director of Alzheimer’s Disease Core

Join to view full profile

Dr. Karlawish is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Karlawish's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Geriatric Medicine (Internal Medicine), 1995 - 1997
  • Johns Hopkins University/Bayview Medical Center
    Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 1991 - 1994
  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 1991

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1997 - 2024
  • IL State Medical License
    IL State Medical License 1994 - 1999
  • MD State Medical License
    MD State Medical License 1993 - 1994
  • American Board of Internal Medicine Geriatric Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Super Doctor SuperDoctors.com

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Desktop Medicine and the Practice of Wealth Care  
    Jason Karlawish, MD, JAMA Internal Medicine
  • Short-Term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment  
    Jeffrey M Burns, Keith A Johnson, Reisa A Sperling, Jason Karlawish, JAMA Neurology
  • Study Partners Should Be Required in Preclinical Alzheimer’s Disease Trials  
    Joshua D Grill, Jason Karlawish, BioMed Central

Authored Content

  • We Can’t Drug Our Way Out of Despair over Alzheimer’s | OpinionAugust 2021
  • Short-Term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive ImpairmentAugust 2020
  • How Bill Gates Could Transform Alzheimer's DiseaseAugust 2018

Press Mentions

  • As Some Families Learn the Hard Way, Dementia Can Take a Toll on Financial Health
    As Some Families Learn the Hard Way, Dementia Can Take a Toll on Financial HealthMay 12th, 2023
  • Slowing, Not Stopping, Alzheimer’s a Better Goal for Drug Trials?
    Slowing, Not Stopping, Alzheimer’s a Better Goal for Drug Trials?February 15th, 2023
  • The Promise of a New Alzheimer’s Drug
    The Promise of a New Alzheimer’s DrugFebruary 7th, 2023
  • Join now to see all

Grant Support

  • Parkinsons Disease And Research Consent CapacityNational Institute Of Neurological Disorders And Stroke2009–2011
  • Core--Education And Information TransferNational Institute On Aging2006–2010
  • Consent Methods And Participation In Geriatric Clinical ResearchNational Institute Of Mental Health2007–2009
  • Understanding Attitudes About Research Advance PlanningNational Institute Of Mental Health2006
  • Improving Informed Consent In Alzheimer Disease ResearchNational Institute On Aging2004–2006
  • Core-- Education And Information TransferNational Institute On Aging2001–2002
  • Community Equipoise And The Ethics Of Clinical ResearchNational Institute On Aging1998–2002

Professional Memberships

Hospital Affiliations

Dr. Jason Karlawish, Dr. Jason Karlawish, MD, Dr. J Karlawish, Dr. Jason H Karlawish